Clinical Trial Update: Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of atezolizumab and bevacizumab with TACE-HAIC for unresectable advanced hepatocellular carcinoma, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING